Static and dynamic interactions between GALK enzyme and known inhibitors: Guidelines to design new drugs for galactosemic patients

Federica Chiappori, Ivan Merelli, Luciano Milanesi, Anna Marabotti

Research output: Contribution to journalArticle

Abstract

The search for inhibitors of galactokinase (GALK) enzyme is interesting for their possible therapeutic application capable to alleviate symptoms in people with classic galactosemia. Several high-throughput screenings in the past have found candidate ligands showing a moderate affinity for GALK. Computational analysis of the binding mode of these compounds in comparison to their target protein has been performed only on crystallographic static structures, therefore missing the evolution of the complex during time. In this work, we applied static and dynamics simulations to analyze the interactions between GALK and its potential inhibitors, while taking into account the temporal evolution of the complexes. The collected data allowed us to identify the most important and persistent anchoring points of the known active site and of the newly identified secondary cavity. These data will be of use to increase the specificity and the affinity of a new generation of GALK inhibitors.

Original languageEnglish
Pages (from-to)423-434
Number of pages12
JournalEuropean Journal of Medicinal Chemistry
Volume63
DOIs
Publication statusPublished - 2013

Fingerprint

Galactokinase
Drug Design
Enzyme Inhibitors
Guidelines
Pharmaceutical Preparations
Galactosemias
Catalytic Domain
Screening
Throughput
Ligands
Computer simulation
Enzymes
Proteins

Keywords

  • Docking
  • Drug discovery
  • Galactosemia
  • Molecular dynamics simulations
  • Pharmacophore
  • Rare disease

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Static and dynamic interactions between GALK enzyme and known inhibitors : Guidelines to design new drugs for galactosemic patients. / Chiappori, Federica; Merelli, Ivan; Milanesi, Luciano; Marabotti, Anna.

In: European Journal of Medicinal Chemistry, Vol. 63, 2013, p. 423-434.

Research output: Contribution to journalArticle

@article{fadfdada5937480f9dc329b11a112e25,
title = "Static and dynamic interactions between GALK enzyme and known inhibitors: Guidelines to design new drugs for galactosemic patients",
abstract = "The search for inhibitors of galactokinase (GALK) enzyme is interesting for their possible therapeutic application capable to alleviate symptoms in people with classic galactosemia. Several high-throughput screenings in the past have found candidate ligands showing a moderate affinity for GALK. Computational analysis of the binding mode of these compounds in comparison to their target protein has been performed only on crystallographic static structures, therefore missing the evolution of the complex during time. In this work, we applied static and dynamics simulations to analyze the interactions between GALK and its potential inhibitors, while taking into account the temporal evolution of the complexes. The collected data allowed us to identify the most important and persistent anchoring points of the known active site and of the newly identified secondary cavity. These data will be of use to increase the specificity and the affinity of a new generation of GALK inhibitors.",
keywords = "Docking, Drug discovery, Galactosemia, Molecular dynamics simulations, Pharmacophore, Rare disease",
author = "Federica Chiappori and Ivan Merelli and Luciano Milanesi and Anna Marabotti",
year = "2013",
doi = "10.1016/j.ejmech.2013.02.021",
language = "English",
volume = "63",
pages = "423--434",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Static and dynamic interactions between GALK enzyme and known inhibitors

T2 - Guidelines to design new drugs for galactosemic patients

AU - Chiappori, Federica

AU - Merelli, Ivan

AU - Milanesi, Luciano

AU - Marabotti, Anna

PY - 2013

Y1 - 2013

N2 - The search for inhibitors of galactokinase (GALK) enzyme is interesting for their possible therapeutic application capable to alleviate symptoms in people with classic galactosemia. Several high-throughput screenings in the past have found candidate ligands showing a moderate affinity for GALK. Computational analysis of the binding mode of these compounds in comparison to their target protein has been performed only on crystallographic static structures, therefore missing the evolution of the complex during time. In this work, we applied static and dynamics simulations to analyze the interactions between GALK and its potential inhibitors, while taking into account the temporal evolution of the complexes. The collected data allowed us to identify the most important and persistent anchoring points of the known active site and of the newly identified secondary cavity. These data will be of use to increase the specificity and the affinity of a new generation of GALK inhibitors.

AB - The search for inhibitors of galactokinase (GALK) enzyme is interesting for their possible therapeutic application capable to alleviate symptoms in people with classic galactosemia. Several high-throughput screenings in the past have found candidate ligands showing a moderate affinity for GALK. Computational analysis of the binding mode of these compounds in comparison to their target protein has been performed only on crystallographic static structures, therefore missing the evolution of the complex during time. In this work, we applied static and dynamics simulations to analyze the interactions between GALK and its potential inhibitors, while taking into account the temporal evolution of the complexes. The collected data allowed us to identify the most important and persistent anchoring points of the known active site and of the newly identified secondary cavity. These data will be of use to increase the specificity and the affinity of a new generation of GALK inhibitors.

KW - Docking

KW - Drug discovery

KW - Galactosemia

KW - Molecular dynamics simulations

KW - Pharmacophore

KW - Rare disease

UR - http://www.scopus.com/inward/record.url?scp=84875018353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875018353&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2013.02.021

DO - 10.1016/j.ejmech.2013.02.021

M3 - Article

C2 - 23517731

AN - SCOPUS:84875018353

VL - 63

SP - 423

EP - 434

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -